[Polymyalgia rheumatica and Giant Cell Arteritis - Update on Diagnosis and Therapy]

Area of Science:

• Rheumatology
• Internal Medicine
• Diagnostic Imaging

Background:

• Polymyalgia rheumatica (PMR) is an inflammatory condition frequently overlapping with Giant Cell Arteritis (GCA).
• PMR diagnosis is often difficult due to non-specific symptoms and numerous differential diagnoses.
• Uncertainty in diagnosis can delay treatment and increase the risk of complications.

Purpose of the Study:

• To provide an update on the diagnosis and therapy of Polymyalgia Rheumatica and Giant Cell Arteritis.
• To highlight advancements in diagnostic tools and therapeutic strategies for PMR and GCA.
• To discuss the impact of new treatments on patient outcomes and side effect profiles.

Main Methods:

• Review of current literature on PMR and GCA diagnosis and treatment.
• Emphasis on the role of ultrasound and other imaging modalities in accelerating diagnosis.
• Evaluation of the efficacy and safety of current and emerging therapies, including glucocorticoids and biologics.

Main Results:

• Imaging techniques like ultrasound have improved diagnostic speed for PMR and GCA, aiding in complication reduction.
• Glucocorticoids remain the cornerstone of initial therapy for both conditions.
• Tocilizumab demonstrates significant efficacy in GCA treatment, offering an alternative to reduce side effects.

Conclusions:

• Advancements in diagnostic imaging expedite the diagnosis of PMR and GCA, potentially preventing severe complications.
• While glucocorticoids are standard, biological therapies like tocilizumab offer improved treatment options for GCA.
• Further research is necessary for GCA complication prevention and screening, but current options enhance therapeutic choices.